Marshall Wace North America’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Marshall Wace North America’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-186,736	Closed	-$1.37M	–	1973
2021 Q1	$1.37M	Buy	+186,736	New	+$1.61M	0.01%	938
2020 Q3	–	Sell	-28,498	Closed	-$147K	–	1606
2020 Q2	$147K	Buy	+28,498	New	+$180K	﹤0.01%	1091
2018 Q2	–	Sell	-1,921	Closed	-$56K	–	1872
2018 Q1	$56K	Hold	1,921	–	–	﹤0.01%	1381
2017 Q4	$54K	Buy	+1,921	New	+$59.6K	﹤0.01%	1326

Other funds holding AVEO

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Marshall Wace North America's AVEO Position: Q2 2021 in Review

Marshall Wace North America sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q2 2021, closing a stake of 186,736 shares — an estimated $1.37M sold.

Marshall Wace North America first reported a position in AVEO in Q4 2017 and held it in 4 quarters. The position peaked at $1.37M in Q1 2021. 63 funds tracked by Wall St. Rank hold AVEO as of Q2 2021.

Marshall Wace North America reported no remaining AVEO Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
Marshall Wace North America sold 186,736 AVEO Pharmaceuticals, Inc. shares in Q2 2021, an estimated $1.37M.
Marshall Wace North America first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2017 and held it in 4 quarters.
Marshall Wace North America's AVEO Pharmaceuticals, Inc. position peaked at $1.37M in Q1 2021.
63 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.